TauRx was established to address one of the world’s biggest challenges – beating Alzheimer’s disease and other degenerative brain disorders through a completely new approach. A leader in Alzheimer’s research, the company’s mission is to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative disorders.
TauRx’s strong research team, supported through cooperative relationships with multiple academic institutions around the world, has focussed on the tau pathway, believed to be one of the critical causes of neurodegeneration in the brain. The company’s novel tau aggregation inhibitors (TAIs) target the formation of tau protein ‘tangles’ in the brain, with its lead compound having shown strong pharmacological effect in trial participants with mild and moderate Alzheimer's disease.
The experimental drug has shown to inhibit aggregation of tau, synuclein, TPD-43 and huntingtin proteins. It is currently in development for the treatment and prevention of Alzheimer’s disease, with a pivotal phase 3 clinical trial underway. A further late stage trial is planned for development of the drug for behavioural variant Frontotemporal Dementia.
Additionally, TauRx works closely with joint venture company Genting TauRx Diagnostics Ltd (GTD) in the development of ground-breaking new diagnostic tools and blood tests for dementia, which will help transform the treatment pathway for those affected, ensure efficient and early diagnosis and enhance access to treatment and care.
TauRx is incorporated in Singapore with primary research and operations in Aberdeen, Scotland.
TauRx’s strong research team, supported through cooperative relationships with multiple academic institutions around the world, has focussed on the tau pathway, believed to be one of the critical causes of neurodegeneration in the brain. The company’s novel tau aggregation inhibitors (TAIs) target the formation of tau protein ‘tangles’ in the brain, with its lead compound having shown strong pharmacological effect in trial participants with mild and moderate Alzheimer's disease.
The experimental drug has shown to inhibit aggregation of tau, synuclein, TPD-43 and huntingtin proteins. It is currently in development for the treatment and prevention of Alzheimer’s disease, with a pivotal phase 3 clinical trial underway. A further late stage trial is planned for development of the drug for behavioural variant Frontotemporal Dementia.
Additionally, TauRx works closely with joint venture company Genting TauRx Diagnostics Ltd (GTD) in the development of ground-breaking new diagnostic tools and blood tests for dementia, which will help transform the treatment pathway for those affected, ensure efficient and early diagnosis and enhance access to treatment and care.
TauRx is incorporated in Singapore with primary research and operations in Aberdeen, Scotland.
Location: United Kingdom, Scotland, Aberdeen
Employees: 51-200
Total raised: $264.5M
Founded date: 2002
Funding Rounds 3
| Date | Series | Amount | Investors |
| 14.11.2022 | - | $119M | - |
| 08.10.2015 | - | $135M | - |
| 05.03.2013 | - | $10.5M | - |
Mentions in press and media 11
| Date | Title | Description |
| 17.10.2024 | Aberdeen Uni Slashes Equity Stake to Boost Spinouts | The University of Aberdeen is to take a new approach to fostering spinout culture by reducing its equity stake in an attempt to increase innovation and accelerate the commercialisation of intellectual property. The move makes Aberdeen one o... |
| 01.12.2022 | LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development | - Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Di... |
| 14.11.2022 | TauRx Raises Additional USD119M in Funding | TauRx Pharmaceuticals, an Aberdeen, UK- and Singapore-based company global leader in tau-based research in Alzheimer’s disease (AD), raised USD119M in funding. The backers were not disclosed. The company intends to use the funds to accelera... |
| 14.11.2022 | TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results | Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market ava... |
| 06.10.2022 | TauRx Announces Results from Phase 3 Alzheimer's Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions | For people with early Alzheimer's (MCI), HMTM treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of brain atrophy to a rate similar to healthy individuals For people with mild to moderate... |
| 01.06.2022 | Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial | LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research Safety profile is favourable and consistent with previous ... |
| 14.04.2022 | TauRx's late-stage clinical trial reaches new milestone | - Significant milestone in the only late-stage clinical trial targeting tau pathology of Alzheimer's - TauRx on track to announce top line results in May - Trial aims to confirm efficacy of first tau-based treatment for Alzheimer's ABERDEEN... |
| 08.10.2015 | TauRx Pharmaceuticals Completes Final Tranche of US$135m Equity Financing | TauRx Pharmaceuticals Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer’s disease, completed the final tranche of a US$135m equity financing that it launched in March. The investment has been provide... |
| 05.03.2013 | TauRx Pharmaceuticals Receives USD10.5M Equity Investment from Dundee Corporation | TauRx Pharmaceuticals Ltd., a Singapore-based company that develops new treatments and diagnostics for a range of neurodegenerative diseases, received a USD10.5m equity investment from Dundee Corporation of Toronto. The company intends to u... |
| 21.11.2012 | TauRx Pharmaceuticals Grabs $31.5M | SINGAPORE, TauRx Pharmaceuticals announced the receipt of a further equity investment of US$31.5M from Genting Management. >> Click here for more funding data on TauRx Pharmaceuticals >> To export TauRx Pharmaceuticals fundi... |
Show more